Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Operating Expenses (2016 - 2025)

Historic Operating Expenses for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to $568491.0.

  • China Pharma Holdings' Operating Expenses rose 50.97% to $568491.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 443.31%. This contributed to the annual value of $2.6 million for FY2024, which is 536.21% up from last year.
  • Latest data reveals that China Pharma Holdings reported Operating Expenses of $568491.0 as of Q3 2025, which was up 50.97% from $565110.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Operating Expenses high stood at $1.2 million for Q4 2022, and its period low was $309647.0 during Q2 2023.
  • In the last 5 years, China Pharma Holdings' Operating Expenses had a median value of $575403.0 in 2023 and averaged $689208.0.
  • As far as peak fluctuations go, China Pharma Holdings' Operating Expenses crashed by 5338.47% in 2021, and later soared by 5024.13% in 2025.
  • China Pharma Holdings' Operating Expenses (Quarter) stood at $950626.0 in 2021, then grew by 27.46% to $1.2 million in 2022, then dropped by 8.78% to $1.1 million in 2023, then decreased by 6.32% to $1.0 million in 2024, then plummeted by 45.1% to $568491.0 in 2025.
  • Its Operating Expenses stands at $568491.0 for Q3 2025, versus $565110.0 for Q2 2025 and $622557.0 for Q1 2025.